Expanded Access Program for LP352 for Patients with Drug-Resistant Epileptic Encephalopathies
Sponsor: Longboard Pharmaceuticals
ClinicalTrials ID:NCT06149663
This program provides ongoing access to the investigational drug LP352 for patients with drug-resistant epileptic encephalopathies (DEEs) who have previously benefited from it in a clinical trial. It is designed for those who have completed an LP352 trial or have a family member with the same genetic condition.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This expanded access program allows patients with drug-resistant epileptic encephalopathies (DEEs) to continue receiving the investigational drug LP352. It is intended for patients who have already participated in an LP352 clinical trial and shown positive results, or for family members with the same genetic mutation causing the same type of epilepsy. The program aims to provide ongoing treatment for those who have benefited from LP352 and meet the eligibility criteria.
Eligibility Criteria
Inclusion Criteria
- The patient or their legal representative must be willing to provide written consent to participate in the program. If the patient is a minor, they should also give their assent if possible.
- The patient must have completed a previous LP352 clinical trial.
- The patient must be experiencing benefits from LP352 treatment, as determined by their doctor.
- The patient must be able to tolerate LP352 without any safety concerns that would prevent continued use.
Exclusion Criteria
- The patient was removed from an LP352 clinical trial for any reason.
- The patient has a new serious or unstable medical condition, psychiatric disorder, or other issues that could affect their safety or ability to participate in the program, according to their doctor.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.